Biophytis S.A.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stanislas Veillet
- Full Time Employees
- 22
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Sorbonne University Paris France 75005
- IPO Date
- Feb 10, 2021
- CIK
- 0001768946
- Website
- biophytis.com
- Similar Companies
- Business
- Biophytis S.A. (ALBPS:PAR; BPTS:US) is a clinical-stage biotechnology company focused on developing small-molecule therapeutics that slow degenerative processes associated with aging and improve functional outcomes in patients with age-related diseases. The company targets biological resilience pathways to counteract stresses such as inflammation, oxidation, metabolism, and viruses that contribute to conditions including sarcopenia, obesity-related muscle wasting, Duchenne muscular dystrophy, and retinal disorders; its lead candidate, Ruvembri (BIO101 or Sarconeos, 20-hydroxyecdysone), is an orally administered small molecule in Phase 3 for sarcopenia-related mobility disability in elderly patients, Phase 2 for muscle wasting in obesity (OBA program), and with a pediatric formulation in early development for Duchenne muscular dystrophy following FDA IND approval; BIO201 (Macuneos) advances for retinal diseases such as dry age-related macular degeneration and Stargardt disease. Biophytis operates a longevity research platform integrating AI-accelerated technologies for drug discovery and maintains clinical programs across the United States, Europe, Brazil, and Asia. Founded in 2006 and headquartered at 14 avenue de l'Opéra in Paris, France, the company employs around 18-22 staff and serves patient populations with limited treatment options in neuromuscular and retinal disease segments. Recent developments include a EUR108 million licensing agreement with Blanver for Ruvembri commercialization in Latin America; a co-development partnership with AskHelpU for amyotrophic lateral sclerosis; exclusive negotiations and a memorandum of understanding for Phase 3 sarcopenia partnerships in China and Asia with a new Hong Kong joint venture backed by up to USD20 million investment; launch of the Phase 2 OBA obesity trial in the US; EUR8.6 million refinancing and EUR2.6 million private placement to strengthen its balance sheet; integration of AI into its drug discovery platform; and approval of all resolutions at its November 13, 2025, general meeting with 31% quorum.
Biophytis Targets Mobility Restoration in Patients with Obesity
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity
Biophytis Revolutionizes Sarcopenia
Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)
Biophytis Unveils Its Outlook Strategies for 2025
Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference
Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China
Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities
Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia
Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity
Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris
Delisting of Securities of PHP Ventures Acquisition Corp.; Green Giant Inc.; RMG Acquisition Corp. III; Biophytis SA; OMNIQ Corp.; AIB Acquisition Corporation; Goal Acquisitions Corp.; Applied UV, Inc.; Cue Health Inc.; Twelve Seas Investment Company II; CalAmp Corp.; and ThermoGenesis Holdings, Inc.; from The Nasdaq Stock Market
Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million
Biophytis Extends Its Contract With Atlas to Secure Financing for Its Business Activities
Biophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider Seqens
Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity
Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity
Biophytis is Deploying its Partnership Strategy in Obesity
Biophytis Announces Transfer of ADSs to OTC Market